Regeneron Pharmaceuticals's Options: A Look at What the Big Money is Thinking
Portfolio Pulse from Benzinga Insights
Big money investors have shown a bearish stance on Regeneron Pharmaceuticals (NASDAQ:REGN), with options trading indicating expectations for the stock's price to range between $660 and $1200 over the next three months. The sentiment among these trades is predominantly bearish, with a significant volume of puts compared to calls. Despite this, analysts have set an average target price of $1143.5 for REGN, with ratings ranging from Buy to Overweight. The current stock price is $920, down 1.73%, and the next earnings report is expected in 21 days.
April 11, 2024 | 4:16 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Bearish big money options trades suggest a potential downside for REGN, despite analyst optimism with a target price of $1143.5.
The bearish sentiment from big money options trades, indicating a price range expectation significantly lower than the current price, suggests a potential short-term downside risk for REGN. This is contrasted by a strong analyst consensus with a higher target price, indicating a mixed outlook that leans towards caution in the short term.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100